A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy.

No Thumbnail Available
Authors
Grubb, A. L.[et al]
McDonald, Timothy J.
Hattersley, Andrew T.
Shields, Beverley M
Jones, Angus G.
Journal
Diabetes care
Type
Journal Article
Publisher
American Diabetes Association
Rights
Archived with thanks to Diabetes care
Progression to insulin therapy in clinically diagnosed type 2 diabetes is highly variable. GAD65 autoantibodies (GADA) are associated with faster progression, but their predictive value is limited. We aimed to determine if a type 1 diabetes genetic risk score (T1D GRS) could predict rapid progression to insulin treatment over and above GADA testing.
Citation
A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody-Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. 2019 Feb;42(2):208-214. Epub 2019 Oct 23. Diabetes Care
Note